Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardinal Health (CAH – Research Report), Agios Pharma (AGIO – Research Report) and Henry Schein (HSIC – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardinal Health (CAH)
Jefferies analyst Brian Tanquilut maintained a Buy rating on Cardinal Health today and set a price target of $270.00. The company’s shares closed last Wednesday at $208.47.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of
Currently, the analyst consensus on Cardinal Health is a Strong Buy with an average price target of $235.54, implying a 12.6% upside from current levels. In a report issued on January 9, Citi also upgraded the stock to Buy with a $244.00 price target.
See today’s best-performing stocks on TipRanks >>
Agios Pharma (AGIO)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Agios Pharma, with a price target of $35.00. The company’s shares closed last Wednesday at $27.17, close to its 52-week low of $27.14.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Currently, the analyst consensus on Agios Pharma is a Moderate Buy with an average price target of $36.14, implying a 35.2% upside from current levels. In a report issued on January 13, TD Cowen also maintained a Buy rating on the stock.
Henry Schein (HSIC)
Bank of America Securities analyst Allen Lutz maintained a Buy rating on Henry Schein today and set a price target of $87.00. The company’s shares closed last Wednesday at $78.94.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $79.75 average price target, which is a 2.1% upside from current levels. In a report issued on January 14, Evercore ISI also maintained a Buy rating on the stock with a $90.00 price target.
